Corporate Retrospective 2007: Daiso
Daiso Co. was founded in 1915 for the electrolytic production of caustic soda from seawater.
Daiso Co. was founded in 1915 for the electrolytic production of caustic soda from seawater. The company was set up in Osaka, Japan, and was called the Osaka Soda Company, Ltd.; the name was changed to the Daiso Co. Ltd. in 1988. The business of the Daiso Co. is centered on industrial chemicals that are of primary importance in various large manufacturing industries. Today, the company has 720 employees and overall revenue over ¥50 billion. With 250 international patents and about 450 in Japan, Daiso has a long-term commitment to product innovation. Daiso is one of the world's largest manufacturers of chromatographic-grade spherical silica gel and in order to expand its presence in North America, Daiso has recently set up a direct sales, marketing, and R&D operation for the preparative and process markets in Santa Clara, California.
Daiso provides fixed-bed flanged chromatography columns, slurry packing service, and bulk media.
With the United States focus on the demanding pharmaceutical market, Daiso's media must deliver consistent performance from analytical through prep to process in the development and commercialization of drug substances. For this purpose, a media was introduced in 2006 to specifically address peptide and protein purification. In addition, the company plans to introduce a series of preparative columns in 2007. Daiso's United States business model, based on vertical integration from media manufacturing through column packing to direct sales and marketing, will permit aggressive pricing for products and services.
Congratulations to LCGC North America on their 25th anniversary.
Dr. Franco Spoldi
Dr. Franco Spoldi
VP Business Development
DAISO Fine Chem USA, INC.
Santa Clara, CA
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
